In a phase I study evaluating ZW25 in HER2-positive solid tumors, four out of nine GC/GEJ cancer patients achieved partial response (PR) [43]; in addition, ZW25 is being evaluated in combination with different chemotherapeutic agents in treatment-naïve HER2-positive patients. This evidence concerns the gene ERBB2 and gastric cancer.